Gilenya

DMT

Discontinuing DMTs Leads to Disease Progression in MS Study

Discontinuation of disease-modifying treatment (DMT) leads to a progression of multiple sclerosis (MS) and a worsening in Expanded Disability Status Scale (EDSS) scores, according to a study published in Multiple Sclerosis and Related Disorders. Patients with relapsing-remitting MS were followed for 5 years during the study and DMT adherence and outcomes were monitored. Over the…

booster shot

Patients With MS on DMT Should Receive COVID-19 Booster, Study Says

The disease-modifying therapy (DMT) cladribine does not compromise the development of a specific humoral response in patients with multiple sclerosis (MS), according to a new study published in Multiple Sclerosis and Related Disorders. “For ocrelizumab and fingolimod, a significant [antibody] response can be achieved with further vaccinations,” the authors of the study wrote. These findings…

Newly Discovered S1P1 Receptor Agonists Show Therapeutic Potential in MS

Researchers developed new sphingosine-1-phosphate-1 (S1P1) receptor agonists called 21l and 21m as potential treatments for multiple sclerosis (MS), as published in the Journal of Medicinal Chemistry. They showed significantly reduced lymphocyte counts in rats. The molecules were also able to delay disease onset and reduce disease incidence in a myelin oligodendrocyte glycoprotein35−55-induced experimental autoimmune encephalitis…

Disease-Modifying Therapies Could Help Protect Patients With MS From COVID-19

Patients with multiple sclerosis (MS) treated with interferon beta-1a (IFN) demonstrated significantly increased humoral responses to the Pfizer mRNA vaccine for COVID-19, according to new study results published in Multiple Sclerosis and Related Disorders. In contrast, patients with MS taking cladribine (CLAD), fingolimod (FTY), and ocrelizumab (OCRE) showed a weakened humoral response. Patients on CLAD,…

Ocular Adverse Events Associated With Multiple Sclerosis Therapies

Several therapies are associated with the development of ocular adverse events in patients with multiple sclerosis (MS), according to a report in Systematic Reviews. Colombian researchers conducted a systematic review of therapies including alemtuzumab (Lemtrada®), amantadine, fingolimod (Gilenya®), steroids, CTLA-4 Ig, estriol, interferon β, natalizumab (Tysabri®), hyperbaric oxygen, rituximab (Rituxan®), siponimod (Mayzent®), teriflunomide (Aubagio®), and…

Gilenya (fingolimod)

Reduced Humoral Response After SARS-CoV-2 Found in MS Patients on Certain Treatments

A new observational study found that multiple sclerosis (MS) patients treated with fingolimod or anti-CD20 monoclonal antibodies (mAbs) developed limited humoral response after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, when compared with untreated patients or those who received other treatments. “Consequently, these patients could be at risk of recurrent infection and could benefit from…

Next post in News Briefs